• Investors
  • News
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
  • Inhalers
    • ICOres
    • ICOcap
    • ICOpre
    • ICOone
    • ICOone Nasal
    • Patents
  • Development capabilities
    • Our inhalers
    • Formulation
    • Pharmaceutical Analysis
  • Pipeline
  • Partner with us
  • Investors
  • Search
  • Menu Menu

    Quarterly Report for Q1 2022 released

    April 29, 2022/in News /by Eva Norell

    The Quarterly Report for Q1 2022 was released today and is available here, in Swedish.

    Share this entry
    • Share on Twitter
    • Share on LinkedIn
    • Share by Mail
    https://www.iconovo.se/wp-content/uploads/2022/06/Nyhetsbilder-.jpg 900 1600 Eva Norell https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png Eva Norell2022-04-29 14:59:482022-06-13 16:08:38Quarterly Report for Q1 2022 released

    Possessing a unique combination

    of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

    ICONOVO AB

    VISITING ADDRESS
    Ideon, Delta 6 Lund
    Ideongatan 3B

    POSTAL ADDRESS
    Iconovo AB
    Ideongatan 3A-B
    SE-223 62 LUND
    Sweden

    CONTACT

    Phone: +46 46 275 67 77

    Director Business Development and Alliances
    Måns Österberg
    Mail: mans.osterberg@iconovo.se

    Interim CEO
    Anders Månsson
    Mail: anders.mansson@iconovo.se

    Press releases

    Subscribe

    Follow us on Linkedin

    Annual Report 2021 released Iconovo and Galenica enters a strategic collaboration for the development of...
    Scroll to top